DVAX Stock Overview
A commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Dynavax Technologies Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.99 |
| 52 Week High | US$15.15 |
| 52 Week Low | US$10.48 |
| Beta | 1.3 |
| 1 Month Change | 2.13% |
| 3 Month Change | -4.61% |
| 1 Year Change | 3.81% |
| 3 Year Change | 33.82% |
| 5 Year Change | 202.02% |
| Change since IPO | -87.24% |
Recent News & Updates
Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S
May 22
Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain
May 10Recent updates
Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S
May 22Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain
May 10Dynavax: Holding Firm Despite Its Missing Cash Cow
Mar 23Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Jan 31These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely
Aug 02Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet
Jun 02We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease
May 03Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly
Jan 16Clover, Dynavax COVID-19 vaccine gets EU GMP certificate
Sep 20Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Sep 12The Alphavaxers: Dynavax And Novavax, 2 Quarters On
Aug 22Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats
Aug 04Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?
Jun 03Dynavax: Evolving Endemic Situation Adds To Its Risk
May 23Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest
May 12Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt
May 10Dynavax Technologies: Full Speed Ahead
Mar 01Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly
Jan 28Dynavax: A Coronavirus Growth Story
Jan 17Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 18The Momentum Investor: Spotlight On Dynavax Technologies
Oct 25Dynavax And TLR Biology: Long-Delayed But Outstanding Success
Oct 16These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Reasonably Well
Oct 02Upgrade: Analysts Just Made A Meaningful Increase To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Forecasts
Aug 10Dynavax: Earnings This Year Ought To Surprise To The Upside
Aug 01Shareholder Returns
| DVAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.3% | -0.4% | -0.6% |
| 1Y | 3.8% | 5.4% | 22.5% |
Return vs Industry: DVAX underperformed the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: DVAX underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| DVAX volatility | |
|---|---|
| DVAX Average Weekly Movement | 4.1% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: DVAX has not had significant price volatility in the past 3 months.
Volatility Over Time: DVAX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 408 | Ryan Spencer | www.dynavax.com |
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B.
Dynavax Technologies Corporation Fundamentals Summary
| DVAX fundamental statistics | |
|---|---|
| Market cap | US$1.57b |
| Earnings (TTM) | US$9.22m |
| Revenue (TTM) | US$236.15m |
170.2x
P/E Ratio6.6x
P/S RatioIs DVAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DVAX income statement (TTM) | |
|---|---|
| Revenue | US$236.15m |
| Cost of Revenue | US$98.47m |
| Gross Profit | US$137.68m |
| Other Expenses | US$128.46m |
| Earnings | US$9.22m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.07 |
| Gross Margin | 58.30% |
| Net Profit Margin | 3.91% |
| Debt/Equity Ratio | 36.1% |
How did DVAX perform over the long term?
See historical performance and comparison